Gout

Low allopurinol prescription rates and suboptimal dosing are of particular concern in adult patients in Asia with poorly controlled gout.

A systematic review of 11 randomized clinical trials found adults with gout exhibited similar hepatic safety profiles for both febuxostat and allopurinol treatment.

Changes in the serum urate levels, number of gout flares before 1 year of treatment, and tophus were linked to the number of gout flares.

All assessed outcomes revealed the treatment effects were significantly better in the external herbal medicine group compared to the control group.

Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.

Males in the highest serum uric acid tier were significantly more likely to be diagnosed with peripheral artery disease, although a similar trend was not observed in female patients.

The incidences of stroke, ischemic heart disease, or heart failure were slightly higher in patients with gout when compared with controls.

A meta-analysis of 7 prospective or retrospective cohort studies conducted in Asia and Europe suggests a diagnosis of gout or hyperuricemia was linked to a lower risk of Alzheimer disease.

After stratifying for gender, age, and ethnicity, hyperuricemia remained positively associated with nephrolithiasis.

Markets with an increased number of rheumatologists had lower costs per patient for emergency room visits and hospitalization compared to areas with a low supply.

Reduced 12-month drug retention rates were seen in patients with concurrent use of hydroxychloroquine, intravenous bDMARD use, and a history of discontinuation of the drug within the first 3 months of the pandemic.

The strongest predictors of hyperuricemia were body mass index, lipid accumulation product, and visceral adiposity index.

Although gout was not associated with hearing loss, hyperuricemia was significantly linked to impairment.

Findings demonstrated Danggui Niantong Decoction combined with conventional Western medicine was more effective in treating gout than Western medicine alone.

The patient-specific definition of gout remission included minimal symptoms, the absence of dietary restrictions, and management strategies to maintain remission.

This follow-up of the MIRROR trial demonstrates significant benefits of coadministration of methotrexate with pegloticase, maintaining the initial findings from observations through 6 months.

The analysis suggested a causal relationship between increased tea intake and overall reduced risk of gout in all 3 gout datasets.

The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.

Tarun Sharma, MD, discusses the overarching trends in treating gout, predictions for the future, and the stigma that often surrounds a gout diagnosis.

Leveraging data from a pair of commercial databases, a new study details the changes in febuxostat prescribing among patients with gout before, during, and after the FDA's addition of a Boxed Warning to prescribing information.

A retrospective analysis of nearly 150 patients with gouty arthritis in China provides further insight into the relationship between pathological ultrasound features and clinical signs and symptoms among this patient population.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.

The pooled analysis showed the risk of all-cause dementia was decreased in patients with gout, particularly in patients receiving medication.

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

Obstructive sleep apnea was linked to an increased risk of gout in the female subgroup.

Women with gout were more likely to exhibit chronic kidney disease, heart failure, dementia, diabetes mellites, and obesity, among others, when compared with men.

The rheumatology month in review highlights a program developed by Janssen to support health equity, the increased risks pregnant women with rheumatic diseases face, and trends in fibromyalgia management.

NHANES data presented at EULAR 2023 offer insight into trends in the risk of mortality over a time period beginning in 1988 and lasting through 2016.

Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.

A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.